Venetoclax
BCL2 inhibitor
- Response rate
- ~70% MRR (relapsed/refractory)
- Onset
- Weeks-months
- Route
- Oral (dose escalation to 400mg daily)
- Line
- 2nd
- IgM effect
- Significant reduction
Evidence summary
BCL2 inhibitor with activity in relapsed/refractory WM, including after BTK inhibitor failure. Being studied in combination with ibrutinib (fixed-duration) and pirtobrutinib. TP53 mutations may predict inferior outcomes. Requires dose escalation due to tumour lysis syndrome risk.